antistaphylococcal polyclonal immunoglobulins

Antistaphylococcal polyclonal immunoglobulins are an experimental passive immunotherapy being developed by the George Eliava Institute of Bacteriophage, Microbiology and Virology. Developed under the Shota Rustaveli National Science Foundation of Georgia grant AR-18-306, this biological agent consists of polyclonal antibodies (primarily IgG) raised in producer animals (such as goats) immunized with specific staphylococcal antigens. These antigens include thermally inactivated Staphylococcus aureus and Staphylococcus epidermidis strains, as well as key pathogenic factors such as alpha-toxin (alpha-anatoxin), Panton-Valentine leukocidin (PV-leukocidin), and hyaluronidase. The therapeutic is designed to neutralize these bacterial toxins and enzymes, prevent tissue damage, and promote opsonophagocytosis of the bacterial cells, offering a potential treatment for complicated staphylococcal infections such as sepsis, meningitis, and endocarditis.

Other names

anti-staphylococcal serumantistaphylococcal polyclonal immunoglobulinGrant AR-18-306polyclonal immunoglobulins for treatment of complicated staphylococcal infectionsstaphylococcal immunoglobulin